An observational study in Periodontitis, sponsored by Atlas University. Completed at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Atlas University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies in Periodontitis with a site in Turkey — 37 open to participants now, 51 under way, none of them phase 3. Periodontitis · Turkey.
Among the 264 studies in Periodontitis with a site in Turkey, this one is the 16th largest by enrollment of the 148 observational ones that give a count, is one of 15 that started in 2018, is one of 148 observational ones, and was the 262nd registered.
1,239 studies on the registry are indexed under Periodontitis; 302 are open to participants now.
Browse Periodontitis studies →37 of the 264 studies in Periodontitis with a site in Turkey are open now. Recruiting first, the newest first:
Ankara University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Abant Izzet Baysal University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Necmettin Erbakan University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
Marmara University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 162 Periodontitis studies recruiting now, 79 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 79 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 4 2
First in 2006; this study’s year is marked. 15 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 90 across 378 observational studies indexed under Periodontitis.
Median enrollment 50 across the 116 interventional studies, 80 across the 148 observational. Of the 208 that completed or were terminated, 1 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 264 has an industry lead sponsor. The 10 most frequent:
Atlas University is the lead sponsor of 97 studies on the registry; 25 are open to participants now.
Atlas University has 1 study filed under Periodontitis — fewer than ten, so there is no comparison to draw.
19 of the studies in Periodontitis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07775378Marmara UniversityBoron Levels, Oxidative Stress, and Inflammation in Periodontitis | 2026-11 |
| NCT07312045Ömer Faruk OkumuşHALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy | 2026-11-25 |
| NCT07887204Istanbul UniversityAntibiotic Resistance Genes in Periodontitis | 2026-12 |
| NCT07146776Saglik Bilimleri UniversitesiTreatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts | 2026-12-01 |
| NCT07942727Ankara UniversityThe Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With Periodontitis | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 264 studies in Periodontitis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational cross-sectional study evaluates the presence and distribution of Candida species in the subgingival area of smokers and non-smokers with Stage II periodontitis. Participants are grouped according to their smoking status. Periodontal clinical parameters, including plaque index, gingival index, bleeding on probing, probing depth, and clinical attachment level, are recorded.
Subgingival samples are collected from selected incisor and molar teeth. Candida species isolated from these samples are identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The study aims to determine whether smoking is associated with differences in the frequency, distribution, and species profile of subgingival Candida colonization in patients with periodontitis.
Periodontitis is a multifactorial inflammatory disease associated with a complex subgingival microbial community. Although bacterial microorganisms are the main focus of periodontal research, fungi such as Candida species may also be present in periodontal pockets and may contribute to the subgingival microbial environment.
Smoking is an established risk factor for periodontal disease and may alter the ecological conditions of the oral cavity. These changes may affect the colonization and persistence of Candida species in periodontal sites. The purpose of this cross-sectional observational study is to evaluate the quantitative and qualitative distribution of subgingival Candida species in smokers and non-smokers diagnosed with generalized Stage II Grade B periodontitis.
Participants are categorized into smoker and non-smoker groups according to their smoking status. Periodontal examinations include assessment of plaque index, gingival index, bleeding on probing, probing depth, and clinical attachment level.
Subgingival microbiological samples are collected from teeth #16, #21, #36, and #41. Samples obtained from single-rooted and multi-rooted teeth are processed separately. Candida growth is assessed using culture methods, and isolated colonies are identified at the species level using MALDI-TOF MS.
The study compares Candida positivity between smokers and non-smokers and evaluates differences according to tooth type and Candida species. The relationships between Candida colonization and clinical periodontal parameters are also assessed.
Adults diagnosed with generalized Stage II Grade B periodontitis who were evaluated at the Department of Periodontology, Faculty of Dentistry, Istanbul Aydin University. Participants were categorized as smokers or non-smokers according to their smoking status and underwent periodontal clinical examination and subgingival sampling for Candida assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of generalized Stage II Grade B periodontitis according to the 2017 World Workshop classification.
Individuals classified as smokers or non-smokers according to their smoking status.
Ability to undergo periodontal clinical examination and subgingival sampling. Provision of written .
Exclusion Criteria:
Systemic diseases that may influence the progression of periodontitis. Recent periodontal treatment. Pregnancy or lactation. Prolonged use of antibiotics or . History of candidiasis. Use of antifungal medications. Physical limitations restricting normal oral hygiene procedures. Smoking 10 or more cigarettes per day.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with generalized Stage II Grade B periodontitis who were classified as smokers according to their smoking status.
Other: Observational
Participants diagnosed with generalized Stage II Grade B periodontitis who were classified as non-smokers according to their smoking status.
Other: Observational
Current cigarette smoking was evaluated as an observational exposure and was not assigned by the investigators. Participants in the smoker group reported smoking fewer than 10 cigarettes per day. Smoking status was self-reported, and no smoking-related intervention or treatment was administered as part of the study.
Prevalence of Subgingival Candida Colonization
The proportion of participants with detectable Candida species in subgingival samples was determined using culture followed by species identification with MALDI-TOF MS and compared between smokers and non-smokers with Stage II Grade B periodontitis.
Time frame: At the baseline study visit
Distribution of Candida Species
The distribution of Candida species identified in subgingival samples, including Candida albicans, Candida dubliniensis, Candida glabrata, and Candida kefyr, was evaluated using MALDI-TOF MS.
Time frame: At the baseline study visit
Plan to share: No — Individual participant data will not be shared because no data-sharing plan was established for this study, and participant-level data are subject to confidentiality and ethical requirements.
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Apr 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atlas University